Boxplot comparing Ct values for HD in flies and clothes. by Philippe Ndzomo (17706039)

S1 Data. Bibliometric analysis. S2 Data. Estrogen level analysis. S3 Data. MicroCT quantification. S4 Data. Markers of bone metabolism. by Yan She (8639796)

Skin marks is the S1 Fig title. by Mercedes Soto-González (20422078)

The significant decrease in GLT-1 levels observed in the nucleus accumbens of rats that had consumed morphine for fifty-six days was completely reversed by the co-administration of... by María Elena Quintanilla (8068691)

Data Sheet 1_Empagliflozin’s cardioenergetic protective effects through PPARα pathway modulation in heart failure.pdf by Hua Wei (60877)

“…Post-treatment, MRGlu and glucose uptake decreased markedly in the empagliflozin (EMPG) group, while no significant changes were observed in the fenofibrate (FF) group. …”

Data extracted from included studies for the systematic review and meta-analysis. by Junyin Pan (20700411)

The basic characteristics of the included studies. by Junyin Pan (20700411)

Common definitions and criteria for metabolic syndrome. by Junyin Pan (20700411)

Assessment of study bias in the included research. by Junyin Pan (20700411)

Results of the effect of dietary anthocyanins on health outcomes, including effect size and heterogeneity analysis. by Junyin Pan (20700411)

Risk of bias assessment for eligible randomized controlled trials. by Junyin Pan (20700411)

Summary of studies identified in the literature search, including studies excluded from the analysis and reasons for exclusion. by Junyin Pan (20700411)

The flow chart of study selection process. by Junyin Pan (20700411)

Specifications and outcomes of clinical trial studies included in the meta-analysis. by Junyin Pan (20700411)

Funnel plot. by Junyin Pan (20700411)

Forest plot. by Junyin Pan (20700411)

Summary of subgroup analysis results. by Junyin Pan (20700411)

“…The results showed that dietary anthocyanins significantly improved various lipid and glycemic markers:</p><p>HDL-C: increased by 0.05 mmol/L (95% CI: 0.01 to 0.10, p = 0.026), LDL-C: decreased by 0.18 mmol/L (95% CI: -0.28 to -0.08, p = 0.000), Triglycerides (TGs): reduced by 0.11 mmol/L (95% CI: -0.20 to -0.02, p = 0.021), Total cholesterol (TC): lowered by 0.34 mmol/L (95% CI: -0.49 to -0.18, p = 0.000), Fasting blood glucose (FBG): reduced by 0.29 mmol/L (95% CI: -0.46 to -0.12, p = 0.001), Glycated hemoglobin (HbA1c): decreased by 0.43% (95% CI: -0.74 to -0.13, p = 0.005). …”

Original study data. by Junyin Pan (20700411)

“…The results showed that dietary anthocyanins significantly improved various lipid and glycemic markers:</p><p>HDL-C: increased by 0.05 mmol/L (95% CI: 0.01 to 0.10, p = 0.026), LDL-C: decreased by 0.18 mmol/L (95% CI: -0.28 to -0.08, p = 0.000), Triglycerides (TGs): reduced by 0.11 mmol/L (95% CI: -0.20 to -0.02, p = 0.021), Total cholesterol (TC): lowered by 0.34 mmol/L (95% CI: -0.49 to -0.18, p = 0.000), Fasting blood glucose (FBG): reduced by 0.29 mmol/L (95% CI: -0.46 to -0.12, p = 0.001), Glycated hemoglobin (HbA1c): decreased by 0.43% (95% CI: -0.74 to -0.13, p = 0.005). …”

S2 File - by Junyin Pan (20700411)

“…The results showed that dietary anthocyanins significantly improved various lipid and glycemic markers:</p><p>HDL-C: increased by 0.05 mmol/L (95% CI: 0.01 to 0.10, p = 0.026), LDL-C: decreased by 0.18 mmol/L (95% CI: -0.28 to -0.08, p = 0.000), Triglycerides (TGs): reduced by 0.11 mmol/L (95% CI: -0.20 to -0.02, p = 0.021), Total cholesterol (TC): lowered by 0.34 mmol/L (95% CI: -0.49 to -0.18, p = 0.000), Fasting blood glucose (FBG): reduced by 0.29 mmol/L (95% CI: -0.46 to -0.12, p = 0.001), Glycated hemoglobin (HbA1c): decreased by 0.43% (95% CI: -0.74 to -0.13, p = 0.005). …”

<i>DRB1*15</i>:<i>01-DQB1*06</i>:<i>02</i> associated protection as a function of iKIR score. by Laura Mora-Bitria (20477525)

“…<p><b>A</b> The ln[OR] of <i>DRB1*15</i>:<i>01-DQB1*06</i>:<i>02</i> decreases (i.e. becomes more protective) as the iKIR score decreases. …”